Persistent mobility disability after neurotoxic chemotherapy

Physical Therapy

Volumn 90, Issue 11, 2010, Pages 1649-1657

  Hile, Elizabeth S ^a   Fitzgerald, G Kelley ^a   Studenski, Stephanie A ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

AGED; ARTICLE; BODY EQUILIBRIUM; BREAST TUMOR; CASE REPORT; CHEMICALLY INDUCED DISORDER; DISABILITY; DRUG EFFECT; FEMALE; HUMAN; MASTECTOMY; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; WALKING DIFFICULTY;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISABILITY EVALUATION; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; MASTECTOMY; MOBILITY LIMITATION; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; POSTURAL BALANCE;

EID: 79952044626     PISSN: 00319023     EISSN: 15386724     Source Type: Journal    
DOI: 10.2522/ptj.20090405     Document Type: Article

References (43)

1. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23:3112-3124. (Pubitemid 46224135)
2. Gilchrist LS, Galantino ML, Wampler M, et al. A framework for assessment in oncology rehabilitation. Phys Ther. 2009;89: 286-306.
3. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994;12:241-248. (Pubitemid 24056395)
4. du Bois A, Schlaich M, Luck HJ, et al. Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Support Care Cancer. 1999;7:354-361. (Pubitemid 29399982)
5. Park SB, Krishnan AV, Lin CS, et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15:3081-3094.
6. Malik B, Stillman M. Chemotherapyinduced peripheral neuropathy. Curr Neurol Neurosci Rep. 2008;8:56-65.
7. Pace A, Bove L, Aloe A, et al. Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci. 1997;18:73-79. (Pubitemid 27238776)
8. Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 2006;6:5.
9. Verstappen CC, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected offtherapy worsening. Neurology. 2005;64: 1076-1077. (Pubitemid 40388469)
10. LoMonaco M, Milone M, Batocchi AP, et al. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol. 1992;239:199-204.
11. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003; 60:337-340. (Pubitemid 36152036)
12. Mold JW, Vesely SK, Keyl BA, et al. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract. 2004;17: 309-318.
13. Visovsky C, Daly BJ. Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy. J Am Acad Nurse Pract. 2004;16:353-359.
14. Argyriou AA, Polychronopoulos P, Koutras A, et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxelbased chemotherapy: could it be predicted? Support Care Cancer. 2005;13: 647-651. (Pubitemid 41040187)
15. Argyriou AA, Polychronopoulos P, Koutras A, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer. 2006;14: 223-229. (Pubitemid 43247926)
16. Visovsky C, Collins M, Abbott L, et al. Putting evidence into practice: evidencebased interventions for chemotherapyinduced peripheral neuropathy. Clin J Oncol Nurs. 2007;11:901-913.
17. Forsyth PA, Balmaceda C, Peterson K, et al. Prospective study of paclitaxelinduced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997;35:47-53. (Pubitemid 27361845)
18. Brienza SVJ, Itzahki M, Krikorian A. Oxaliplatin (L-OHP): Global safety in 682 patients (abstract 513). Proc Am Soc Clin Oncol. 1995;14:209.
19. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB III. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994;12:2447-2452. (Pubitemid 24346719)
20. Verdu E, Ceballos D, Vilches JJ, Navarro X. Influence of aging on peripheral nerve function and regeneration. J Peripher Nerv Syst. 2000;5:191-208. (Pubitemid 32037991)
21. Pratt RW, Weimer LH. Medication and toxin-induced peripheral neuropathy. Semin Neurol. 2005;25:204-216. (Pubitemid 40847570)
22. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85-M94. (Pubitemid 24100267)
23. Fitti JE, Kovar MG. The Supplement on Aging to the 1984 National Health Interview Survey. Vital Health Stat 1. 1987:21-115.
24. Nevitt MC, Cummings SR, Kidd S, Black D. Risk factors for recurrent nonsyncopal falls: a prospective study. JAMA. 1989;261: 2663-2668. (Pubitemid 19127961)
25. Seeman TE, Charpentier PA, Berkman LF, et al. Predicting changes in physical performance in a high-functioning elderly cohort: MacArthur studies of successful aging. J Gerontol. 1994;49:M97-M108. (Pubitemid 24143193)
26. Winograd CH, Lemsky CM, Nevitt MC, et al. Development of a physical performance and mobility examination. J Am Geriatr Soc. 1994;42:743-749. (Pubitemid 24213196)
27. Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995; 332:556-561.
28. Studenski S, Perera S, Wallace D, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc. 2003;51: 314-322. (Pubitemid 36348892)
29. Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221-M231. (Pubitemid 30257618)
30. Postma TJ, Heimans JJ, Muller MJ, et al. Pitfalls in grading severity of chemotherapy- induced peripheral neuropathy. Ann Oncol. 1998;9:739-744. (Pubitemid 28394160)
31. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54:743-749. (Pubitemid 44030194)
32. Dougherty PM, Cata JP, Cordella JV, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109:132-142. (Pubitemid 38479779)
33. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
34. Sarafraz M, Ahmadi K. Paraclinical evaluation of side-effects of Taxanes on auditory system. Acta Otorhinolaryngol Ital. 2008; 28:239-242.
35. Wampler MA, Topp KS, Miaskowski C, et al. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil. 2007;88: 1002-1008. (Pubitemid 47126397)
36. Podsiadlo D, Richardson S. The timed "up & go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142-148.
37. Stafford RS, Cyr PL. The impact of cancer on the physical function of the elderly and their utilization of health care. Cancer. 1997;80:1973-1980. (Pubitemid 27479793)
38. Demark-Wahnefried W, Clipp EC, Morey MC, et al. Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. J Clin Oncol. 2006;24: 3465-3473. (Pubitemid 46638905)
39. Garman KS, Pieper CF, Seo P, Cohen HJ. Function in elderly cancer survivors depends on comorbidities. J Gerontol A Biol Sci Med Sci. 2003;58:M1119-M1124.
40. Wampler MA, Hamolsky D, Hamel K, et al. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs. 2005;9: 189-193.
41. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
42. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
43. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version in Clinical Gerontology: A Guide to Assessment and Intervention. New York, NY: The Haworth Press; 1986:165-173.